Visit Boston Millennia Partners  
   
 

AthenixBoston, MA — November 4, 2009 — Boston Millennia Partners (BMP II) is pleased to announce that its portfolio company, Athenix Corporation, has been acquired by Bayer CropScience for $400 million. This is the second BMP II portfolio company sold for a 10X return.

Dana Callow, Managing General Partner at Boston Millennia Partners said, “This high value sale was the result of Athenix’s unique intellectual property, as well as superior execution of several development programs by its management team. We congratulate Athenix’s Chief Executive, Michael Koziel, and his entire team for achieving this outstanding result.”

Athenix discovers and develops proprietary productivity-enhancing crop traits for corn, soybean and other commercial crops. The management team spun out of DuPont Pioneer in 2001 and leveraged decades of experience in trait discovery to build a platform technology that created one of the largest libraries of agronomic traits in the industry.  By making the strategic decision to establish partnerships with other industry participants, including DuPont, Syngenta, Monsanto, and others,  Athenix was able to accelerate development, access distribution, build its balance sheet and achieve visibility with potential purchasers such as Bayer.

“Mike and his management team combined strong science and sound strategy to achieve this great result”, said Rob Jevon, Boston Millennia Partner and Director of Athenix from inception of Millennia’s Series A investment in Athenix. “BMP is proud to have been part of the Athenix story, whose products will provide significant benefits to farmers and consumers.  We wish Mike and his team continued success with Bayer.”

About Athenix

Athenix, founded in 2001, is a leading biotechnology company that develops novel products and technologies for agricultural and industrial applications. Athenix has established an outstanding intellectual property portfolio and market access ability around enhanced plants, microbes, genes, enzymes, and processes with emphasis on two major markets: 1) novel agricultural traits for growers such as insect resistance, nematode resistance, herbicide tolerance, and their use for the crop production industry; and 2) the discovery of genes and proteins for use in the sustainable chemical industry. For more information visit www.athenixcorp.com.




 
 


Our Firm

Our Team

Our Portfolio

Latest News

 
 


Boston Millennia Partners is a private equity investment partnership managing over $700 million in capital. From its offices in Boston, Millennia invests in high-growth business in healthcare, life sciences, and business services industries. Typical investments range from $5 to $20 million. The managers at Millennia have funded over 120 companies in the U.S. private equity market since 1980. Significant portfolio companies with whom they have invested include Athenix/Bayer CropScience a subsidiary of Bayer AG (BAYN GR), PAREXEL International (NASDAQ-GS PRXL), GlycoFi/Merck (NYSE: MRK), Galt/Cerner (NASDAQ-GS: CERN), ILEX Oncology/Genzyme Oncology (NASDAQ-GS: GENZ),Verio/NTT (NYSE: NTT), HotJobs/Yahoo (NASDAQ-GS: YHOO), Proteome/Incyte Genomics (NASDAQ-GM: INCY) and P&H Solutions/ACI Worldwide NASDAQ-GS: ACIW), among others. For more information, please visit http://www.bmpvc.com/.

Contact:
Amy Merk
Boston Millennia Partners
617-428-5150
amy@bmpvc.com


 
     
 
Boston Millennia Partners

30 Rowes Wharf
Suite 400
Boston, MA 02110
Phone: 617-428-5150
Fax: 617-428-5160

E-mail: info@bmpvc.com

 
  ©2009 Boston Millennia Partners  All Rights Reserved